Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2010. Supporting Information for *Macromol. Biosci.*, DOI: 10.1002/mabi.200900295.

## Synthesis and Characterization of Enzymatically Degradable PEG-Based Peptide-Containing Hydrogels

Jiyuan Yang<sup>a</sup>, Michael T. Jacobsen<sup>a</sup>, Huaizhong Pan<sup>a</sup>, Jindřich Kopeček<sup>a,b,\*</sup>

Departments of <sup>a</sup>Pharmaceutics and Pharmaceutical Chemistry/CCCD, and of

<sup>b</sup>Bioengineering, University of Utah, Salt Lake City, Utah 84112, USA

\*Corresponding author: Jindřich Kopeček, Center for Controlled Chemical Delivery, 20 S 2030 E, BPRB 205B, University of Utah, Salt Lake City, UT 84112-9452, USA. Phone: (801) 581-7211; Fax: (801) 581-7848.

E-mail address: jindrich.kopecek@utah.edu (J. Kopeček)

RP-HPLC and MALDI-TOF MS of Peptides GFLG1 and GFLG2

The purity of the peptides was verified with analytical RP-HPLC (Agilent Technologies 1100, equipped with Zorbax 300SB-C18 column, 4.6 × 250 mm, 300 Å pore size, 5 µm particle size, flow rate 1.0 mL/min) employing a gradient from 2% to 90% B over 25 min, where Buffer A was 0.1% TFA in water and Buffer B 0.1% TFA in acetonitrile (**Figure S1** and **S2**). Peptide structures were ascertained by MALDI-TOF mass spectra (Voyager-DE STR Biospectrometry Workstation, Perseptive Biosystems) shown as **Figure S3** and **Figure S4**, respectively.




Figure S1. RP-HPLC of Peptide GFLG1




Figure S2. RP-HPLC of Peptide GFLG2





Figure S3. MALDI-TOF MS of Peptide GFLG1



**Figure S4**. MALDI-TOF MS of Peptide GFLG2